Suchergebnisse - "Quashie, Peter K"

PubPharm (8)

1

The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B

enthalten in: AIDS (London, England) | 2015

von Mesplède, T. | Quashie, P. | Hassounah, S. | +5

2

Structural Studies of the HIV-1 Integrase Protein : Compound Screening and Characterization of a DNA-Binding Inhibitor

enthalten in: PloS one | 2015

von Quashie, P. | Han, Y. | Hassounah, S. | +2

3

HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase

enthalten in: Antimicrobial agents and chemotherapy | 2014

von Depatureaux, A. | Quashie, P. | Mesplède, T. | +7

4

Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors

enthalten in: Journal of virology | 2014

von Hassounah, S. | Mesplède, T. | Quashie, P. | +3

5

The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness

enthalten in: Retrovirology | 2014

von Wares, M. | Mesplède, T. | Quashie, P. | +3

6

Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase

enthalten in: Antimicrobial agents and chemotherapy | 2013

von Quashie, P. | Mesplède, T. | Han, Y. | +6

ErratumIn: Antimicrob Agents Chemother. 2014 Jan;58(1):633

7

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

enthalten in: Retrovirology | 2013

von Mesplède, T. | Quashie, P. | Osman, N. | +6

8

Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir

enthalten in: Journal of virology | 2012

von Quashie, P. | Mesplède, T. | Han, Y. | +5

1
[1]